August 05, 2020
1 min read
Save

Delgocitinib receives fast track designation for chronic hand eczema

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA has granted fast track designation to delgocitinib cream for the potential treatment of moderate to severe chronic hand eczema in adults, Leo Pharma announced in a press release.

An investigational topical pan-Janus kinase inhibitor, delgocitinib inhibits activation of the JAK-STAT pathway, which drives the pathophysiology of chronic inflammatory skin diseases, the release said.

“Moderate to severe CHE can be a disabling skin disease that can disrupt the ability for people to work and be self-sufficient because their hands can feel so raw and painful,” Kim Kjøller, MD, executive vice president, global research and development, Leo Pharma, said in the release. “We are delighted that topical delgocitinib cream has been granted fast track designation and look forward to collaborating with the FDA during the development process as we aim to accelerate bringing this potential new treatment option to patients.”